Refine by MP, party, committee, province, or result type.

Results 1-6 of 6
Sorted by relevance | Sort by date: newest first / oldest first

Health committee  I can comment about the findings you mentioned about information we have available. It is true we have a lot of information available over the Internet about different drugs, but sadly, most of that information is not evidence based. A lot of patients in my practice go to the In

February 28th, 2008Committee meeting

Irfan Aslam

Health committee  Minor adverse drug reactions are quite common. In my practice I see maybe once a week a minor reaction. But if you're talking about something that is really serious, that is very rare, Andrew was talking about 176. So you can see that in all of Canada there were only 176 events t

February 28th, 2008Committee meeting

Irfan Aslam

Health committee  There is no particular criterion. However, when we see that this drug is not acting in a way that it is supposed to act.... We can get the information. Right now we are getting other professionals--doctors and pharmacists--to get that information. There are side effects attached

February 28th, 2008Committee meeting

Irfan Aslam

Health committee  My other colleagues here from CMA have also commented on that. Right now, under the reporting system, there is no obligation on health care professionals to report. However, in my experience and according to the last literature search I've done, most of the physicians and other

February 28th, 2008Committee meeting

Irfan Aslam

Health committee  In my own experience, I have not actually seen this happening. Usually it is done in the form of a group, so if a nurse or doctor noticed an adverse effect, they would discuss it with each other. After that, it would be reported. If you were taking a scenario in which one perso

February 28th, 2008Committee meeting

Irfan Aslam

Health committee  My name is Irfan Aslam, and I will go on with another recommendation. Recommendation five is to ensure that Canadians are informed of any pharmaceutical product approval and non-approval in an open-access system that includes a summary of the rationale for approval or non-appro

February 28th, 2008Committee meeting

Irfan Aslam